EUVIMEDEUVIMED entdecken
Crossref

Increased plasma miR-370-3p expression in poor-outcome patients with pancreatic ductal adenocarcinoma

Takumi Harada, Kenichiro Uemura, Tatsuaki Sumiyoshi, Ryuta Shintakuya, Kenjiro Okada, Tetsuhiro Hara, Shinya Takahashi, Eiso Hiyama

Pancreatology · 2023

DOI: 10.1016/j.pan.2023.10.019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pancreatology, 2023. Verfasst von Takumi Harada und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, MicroRNAs. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To determine whether circulating microRNAs (miRNAs) can be used as prognostic biomarkers for pancreatic ductal adenocarcinoma (PDAC). METHODS: Patients with PDAC (N = 120) who underwent surgical resection at Hiroshima University Hospital between November 2006 and January 2020 were enrolled in this study and grouped based on their overall survival (OS) into two groups: favorable prognosis group (F group; OS ≥ 18 months) and unfavorable prognosis group (U group; OS < 18 months). Blood plasma samples were collected prior to surgery. To identify candidate prognostic miRNAs, next-generation sequencing (NGS) analysis was used to evaluate the expression levels of miRNAs in seven of the plasma samples. Using quantitative real-time PCR (qRT-PCR), the expression levels of the selected miRNAs were determined in the remaining 113 patient plasma samples, and the relationship between miRNA expression and survival was statistically evaluated. RESULTS: NGS analysis and qRT-PCR revealed significantly upregulated plasma miR-370-3p expression in the U group compared to that in the F group (p = 0.028 and p = 0.005, respectively). Moreover, miR-370-3p expression and lymph node metastasis showed a statistically significant association (p = 0.028). In a multivariate analysis of OS and recurrence-free survival (RFS), the upregulation of miR-370-3p expression in plasma was identified as an independent risk factor for poor OS (HR2.13, p = 0.004) and RFS (HR1.84, p = 0.015). CONCLUSIONS: Plasma miR-370-3p expression upregulation correlates with poor prognosis in patients with PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalMicroRNAsHumansPrognosisGene Expression Regulation, NeoplasticBiomarkers, Tumor

Stichwörter der Autor:innen

BiomarkerPancreatic ductal adenocarcinomamiR-370microRNA

Substanzen

MicroRNAsBiomarkers, TumorMIRN370 microRNA, human

Autor:innen und Institutionen

  • Department of Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Natural Science Center for Basic Research and Development, Hiroshima University, Hiroshima, Japan. Electronic address: eiso@hiroshima-u.ac.jp.

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science

Zitieren

APA

Harada, T., Uemura, K., Sumiyoshi, T., Shintakuya, R., Okada, K., Hara, T., Takahashi, S., & Hiyama, E. (2023). Increased plasma miR-370-3p expression in poor-outcome patients with pancreatic ductal adenocarcinoma. Pancreatology. https://doi.org/10.1016/j.pan.2023.10.019

Vancouver

Harada T, Uemura K, Sumiyoshi T, Shintakuya R, Okada K, Hara T, et al. Increased plasma miR-370-3p expression in poor-outcome patients with pancreatic ductal adenocarcinoma. Pancreatology. 2023. doi:10.1016/j.pan.2023.10.019

BibTeX
@article{Harada2023,
  author = {Harada, Takumi and Uemura, Kenichiro and Sumiyoshi, Tatsuaki and Shintakuya, Ryuta and Okada, Kenjiro and Hara, Tetsuhiro and Takahashi, Shinya and Hiyama, Eiso},
  title = {Increased plasma miR-370-3p expression in poor-outcome patients with pancreatic ductal adenocarcinoma},
  journal = {Pancreatology},
  year = {2023},
  doi = {10.1016/j.pan.2023.10.019}
}
Kostenlos starten →